FMO5 and cardiac hypertrophy: However, genetic modification resulting in inactivation of the gp91phox subunit, a vital component within NADPH oxidase, in transgenic mice did not show significant benefits to alleviate Ang II-induced hypertension or cardiac hypertrophy (Touyz et al., 2005).